Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

【24h】

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

机译：基于年龄在高级肾细胞癌患者的Cabozantinib患者的III阶段流星试验的成果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Cabozantinib improved progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) compared with everolimus in patients with advanced renal cell carcinoma (RCC) after prior antiangiogenic therapy in the phase III METEOR trial (NCT01865747). Limited data are available on the use of targeted therapies in older patients with advanced RCC.

机译：背景：与先进的肾细胞癌（RCC）在第三阶段流星审判中的抗血管生成治疗（NCT01865747）之前，Cabozantinib改善了无进展的存活率（PFS），总体存活率（OSR），整体存活率（ORR）与血管内癌癌（RCC）患者（RCC）患者。有限的数据可用于在高级RCC患者中使用有针对性的疗法。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2020年第2020期|共10页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Age; Cabozantinib; Everolimus; METEOR; Renal cell carcinoma; Tyrosine kinase inhibitor; Vascular endothelial growth factor receptor;

机译：年龄;cabozantib;everolimus;流星;肾细胞癌;酪氨酸激酶抑制剂;血管内皮生长因子受体;

相似文献

外文文献
中文文献
专利

1. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma [J] . European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2020,第期

机译：基于年龄在高级肾细胞癌患者的Cabozantinib患者的III阶段流星试验的成果
2. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma [J] . Thomas Powles, Robert J. Motzer, Bernard Escudier, British Journal of Cancer . 2018,第6期

机译：卡博替尼与依维莫司在晚期肾细胞癌的3期METEOR试验中基于先前治疗的结果
3. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma [J] . Thomas Powles, Robert J. Motzer, Bernard Escudier, British Journal of Cancer . 2018,第6期

机译：卡博替尼与依维莫司在晚期肾细胞癌的3期METEOR试验中基于先前治疗的结果
4. Designing Phase III Trials in Metastatic Renal Cell Carcinoma: What Are the New Standards? [C] . Ana M. Molina Genitourinary Cancers Symposium . 2012

机译：在转移性肾细胞癌中设计III期试验：新标准是什么？
5. Renal Cell Carcinoma in End Stage Renal Disease Patients: An Institutional Review [D] . Nolte, Adam. 2019

机译：肾细胞癌在末期肾病患者：制度综述
6. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma [O] . Thomas Powles, Robert J. Motzer, Bernard Escudier, 2018

机译：卡波替尼与依维莫司在晚期肾细胞癌的3期METEOR试验中基于先前治疗的结果
7. Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma [O] . Nizar M. Tannir, Thomas Powles, Bernard Escudier, 2020

机译：流星肾切除术地位的临床结果，随机相3试验Cabozantib对患者肾细胞癌的患者

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

摘要

著录项

相似文献

相关主题

期刊订阅